UCLA Prostate Cancer Index: Functional Assessment of Prostate-Specific QoL
UCLA Prostate Cancer Index · Also known as: UCLA PCI, PCI
The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
UCLA PCI is indicated for men with prostate cancer undergoing or having undergone any treatment (surgery, radiation, hormone therapy, surveillance). Primary use is treatment outcome studies comparing surgical vs. radiation vs. hormone therapy or surveillance in terms of functional outcomes; secondary use in oncology clinic baseline and monitoring of functional side effects. NOT for general cancer QoL assessment (use FACT-P for comprehensive QoL); NOT for screening or diagnosis. Particularly suited for functional outcomes research and clinical decision-making around treatment selection based on functional priorities.
Strengths & limitations
- Narrowly focused on functional outcomes (urinary, sexual, bowel) most relevant to prostate cancer patients; avoids extraneous general-QoL content.
- Excellent discriminative validity for comparing functional outcomes across treatment modalities (surgery vs. radiation vs. hormone therapy); sensitive to treatment-specific side effects.
- Brief (20 items, or 15 items in short form) with rapid administration and completion.
- Extensively validated in large prostate cancer outcome studies and prospective cohorts; published MCID estimates available.
- Widely adopted in Prostate Cancer Outcomes Study (PCOS), Shared Reporting of Decentralized Trials (PROTECT) and other major prostate cancer research initiatives.
- Does not assess general cancer QoL, emotional well-being, or social functioning; comprehensive prostate cancer QoL assessment requires supplementary scales (e.g., FACT-P or FACT-G).
- Functional domain items vary in response format, increasing respondent burden for item interpretation (frequency scales, yes/no items, Likert items mixed).
- Sexual function items assume heterosexual partnered activity; less applicable to single, post-menopausal, or same-sex partnered men without additional validation.
- Bother items are non-standardized (qualitative descriptors); difficult to compare quantitatively across patients or studies.
Frequently asked
Can UCLA PCI be used in men on active surveillance?
Yes. UCLA PCI is appropriate for all prostate cancer statuses including active surveillance. Surveillance men typically have higher (better) UCLA PCI scores than treatment-group men, reflecting no treatment-related dysfunction. Longitudinal UCLA PCI can assess surveillance anxiety and QoL; scores should remain stable or improve if surveillance is tolerated well.
How does UCLA PCI compare to FACT-Prostate (FACT-P)?
UCLA PCI (20 items) is narrowly focused on functional outcomes (urinary, sexual, bowel); no general cancer QoL or emotional content. FACT-P (39 items) includes 27-item FACT-G general cancer core plus 12-item prostate subscale; comprehensive QoL assessment. UCLA PCI ideal for functional outcomes research; FACT-P for comprehensive QoL trials. Both valid; use depends on research question and needed outcome domains.
What is the MCID for UCLA PCI domain scores?
MCID for UCLA PCI domain scores is approximately 10–15 points on 0–100 scale (varies slightly by domain). In comparative treatment studies, a ≥10-point difference in domain score between treatment groups suggests clinically meaningful functional difference. Change scores (baseline to follow-up) of ≥MCID indicate meaningful treatment-related functional change.
Can UCLA PCI be used in metastatic prostate cancer?
UCLA PCI is validated across prostate cancer stages including metastatic disease. However, metastatic patients may have competing symptoms (bone pain, fatigue) that overshadow functional concerns. For advanced/palliative prostate cancer, consider supplementary pain and symptom scales alongside UCLA PCI; focus may shift from functional recovery to symptom management.
How are missing data handled in UCLA PCI scoring?
If >50% of items in a domain are missing, do not score that domain. If ≤50% are missing, impute the mean of completed items per domain. Domain-specific imputation is standard. Report number of missing items per domain; avoid interpretation if data completeness is <80%.
Is UCLA PCI free and available in multiple languages?
UCLA PCI is publicly available for research use (no licensing fees). The instrument is available via UCLA (humanism.ucla.edu) and has been translated into 10+ languages. Use validated translations to preserve psychometric properties; informal translations are not recommended.
Sources
- Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. DOI: 10.1097/00005650-199807000-00007 ↗
- Litwin, M. S., & Tan, H. J. (2017). The diagnosis and treatment of prostate cancer: a review. JAMA, 317(24), 2532–2542. DOI: 10.1001/jama.2017.7248 ↗
How to cite this page
ScholarGate. (2026, June 3). UCLA Prostate Cancer Index. ScholarGate. https://scholargate.app/en/oncology/ucla-prostate-cancer-index
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Cancer Worry ScaleOncology↔ compare
- EORTC QLQ-BR23Oncology↔ compare
- EORTC QLQ-LC13Oncology↔ compare
- FACT-LungOncology↔ compare
- FACT-ProstateOncology↔ compare